ALK and non-small cell lung carcinoma: First-(crizotinib) and second-(ceritinib, alectinib, brigatinib) generation TKIs are approved for the front-line treatment of ALK-positive advanced NSCLC patients, in light of their positive effect on survival compared to chemotherapy [32,33].